By Chris Wack

Immunocore Holdings Plc shares rose 10% to $33.87 after the company said it has entered into a clinical trial collaboration and supply agreement with Sanofi.

Under the agreement, Sanofi will evaluate SAR444245 in combination with Kimmtrak, Immunocore's novel bispecific protein targeting gp100, in HLA-A*02:01 positive patients with advanced unresectable or metastatic skin cancers as part of Sanofi's ongoing Phase 1/2 study.

Sanofi will be responsible for clinical development and will assume all costs associated with the study, other than expenses related to the manufacturing and supply of Kimmtrak, for which Immunocore is responsible.

In January 2022 and April 2022, the U.S. Food and Drug Administration and the European Commission, respectively, approved Kimmtrak tebentafusp for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.

Immunocore is planning a randomized study of Kimmtrak with or without anti-PD1 therapy in patients with metastatic melanoma and anticipates initiating the trial in the fourth quarter of 2022.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

June 03, 2022 11:06 ET (15:06 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Historical Stock Chart
Von Mär 2024 bis Apr 2024 Click Here for more Sanofi Charts.
Sanofi (EU:SAN)
Historical Stock Chart
Von Apr 2023 bis Apr 2024 Click Here for more Sanofi Charts.